Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification

Despite its generally favorable prognosis at primary diagnosis, recurrence of endometrial cancer remains an important clinical challenge. The aim of this study was to analyze the value of molecular classification in recurrent endometrial cancer. This study included patients with recurrent endometrial cancer who underwent primary surgical treatment between 2004 and 2015 at the Karolinska University Hospital, Sweden and the Bern University Hospital, Switzerland (KImBer cohort) with molecular classification of the primary tumor. Out of 594 molecularly classified endometrial cancer patients, 101 patients experienced recurrence, consisting of 2 POLEmut, 33 MMRd, 30 p53abn, and 36 NSMP tumors. Mean age at recurrence was 71 years and mean follow-up was 54 months. Overall, median time to first recurrence was 16 months (95% CI 12–20); with the shortest median time in MMRd patients, with 13 months (95% CI 5–21). The pattern of recurrence was distinct among molecular subgroups: MMRd tumors experienced more locoregional, while p53abn cases showed more abdominal recurrences (P = .042). Median survival after recurrence was best for MMRd cases (43 months, 95% CI 11–76), compared to 39 months (95% CI 21–57) and 10 months (95% CI 7–13) for the NSMP and p53abn cases respectively (log-rank, P = .001). Molecular classification is a significant indicator of survival after recurrence in endometrial cancer patients, and patterns of recurrence differ by molecular subgroups. While MMRd endometrial cancer show more locoregional recurrence and the best survival rates after recurrence, p53abn patients experience abdominal recurrence more often and had the worst prognosis of all recurrent patients. [Display omitted] •The pattern of recurrence in endometrial cancer differs among the molecular subgroups.•Molecular classification of the primary tumor in endometrial cancer is a significant predictor of survival after recurrence.•MMRd endometrial cancer patients experience more locoregional recurrences and show the best survival after recurrence.•p53abn endometrial cancer patients have the worst survival rate after recurrence.